Vaxart (VXRT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025 4:05 PM EDTReported positive topline data from Phase 1 clinical trial evaluating Companys second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Â
Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues
Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026
Conference call today at 4:30 p.m. ET
Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently... More
